ENGN detalimogene advances toward BLA filing planned for 4Q 2026
Detalimogene advanced toward regulatory milestones with pivotal data updates and a BLA filing planned for 4Q 2026. Interim results indicate promising efficacy in NMIBC, supported by a strong cash position.
Detalimogene advanced toward regulatory milestones with pivotal data updates and a BLA filing planned for 4Q 2026. The company said its strong cash position supports operations, while interim results showed promising efficacy in NMIBC. It also said a board leadership transition and FDA designations have improved commercial readiness.